Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Pleural Effusion Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

(MENAFN- GlobeNewsWire - Nasdaq) The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

A 46-year-old man with advanced lung cancer recovered after doctors used Next Generation Sequencing to identify a rare ALK fusion mutation and treat him with targeted therapy instead of chemotherapy.

A 69-year-old man presented with a 2-year history of changes in bowel habits, including abdominal cramps, constipation, and ...

However, the causative organism was not identified until 1992 by molecular methods and was initially named Tropheryma ...

Wuhan YZY Biopharma Co., Ltd. Class H ( ($HK:2496) ) has provided an announcement. Wuhan YZY Biopharma Co., Ltd. announced that the Phase II ...

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...